Skip to main content

Peer Review reports

From: Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study

Original Submission
24 Mar 2021 Submitted Original manuscript
30 Mar 2021 Reviewed Reviewer Report - Carmel stock
5 Apr 2021 Reviewed Reviewer Report
27 Apr 2021 Author responded Author comments - Sheng-Hsiang Lin
Resubmission - Version 2
27 Apr 2021 Submitted Manuscript version 2
29 Apr 2021 Author responded Author comments - Sheng-Hsiang Lin
Resubmission - Version 3
29 Apr 2021 Submitted Manuscript version 3
5 May 2021 Reviewed Reviewer Report
7 May 2021 Reviewed Reviewer Report - Carmel stock
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
7 May 2021 Editorially accepted
15 May 2021 Article published 10.1186/s12890-021-01530-6

You can find further information about peer review here.

Back to article page